Dawei Cai1, Wan Feng2, Qing Jiang1. 1. Department of Orthopedics, Drum Tower Hospital, Nanjing University Medical School No. 321 Zhongshan Road, Nanjing, China. 2. Nanjing University Medical School Nanjing, People's Republic of China.
Abstract
BACKGROUND: Acid-suppressive medications are widely used for the management of acid-related disorders. It has been reported that acid-suppressive medication users were at increased risk of fracture, but such an association was inconsistent among observational studies. The purpose of our analysis was to assess the relationship between use of antacid drugs and fracture risk. METHODS: We systematically searched electronic database and manually examined the reference lists of previous reviews for potentially eligible studies. Given the heterogeneity across studies, random effects models were used to calculate summary estimates. Subgroup analysis and sensitivity analysis were conducted to explore the potential heterogeneity. RESULTS: 18 studies met our inclusion criteria. PPI and H2RA were associated with increased risk of hip fracture, with substantial heterogeneity (PPI: 1.216, 1.134-1.304, I(2)=71.3%; H2RA: 1.128, 1.022-1.245, I(2)=72.1%). High risk of spine fracture was observed in PPI users (1.216, 95% CI: 1.134-1.304) but not H2RA users. When considering 5 studies conducted among postmenopausal women, the RR was 1.376, (95% CI: 1.043-1.816) with modest heterogeneity (I(2)=57.7%). Subgroup analysis and sensitivity analysis found consistent association between hip fracture risk and PPI use but not H2RA use. Positive association for H2RA use lost its significance when considering case-control studies and European studies. CONCLUSION: Results of this updated meta-analysis provided evidence to support that acid-suppressive medications were associated with increased risk of fracture, especially hip fracture.
BACKGROUND: Acid-suppressive medications are widely used for the management of acid-related disorders. It has been reported that acid-suppressive medication users were at increased risk of fracture, but such an association was inconsistent among observational studies. The purpose of our analysis was to assess the relationship between use of antacid drugs and fracture risk. METHODS: We systematically searched electronic database and manually examined the reference lists of previous reviews for potentially eligible studies. Given the heterogeneity across studies, random effects models were used to calculate summary estimates. Subgroup analysis and sensitivity analysis were conducted to explore the potential heterogeneity. RESULTS: 18 studies met our inclusion criteria. PPI and H2RA were associated with increased risk of hip fracture, with substantial heterogeneity (PPI: 1.216, 1.134-1.304, I(2)=71.3%; H2RA: 1.128, 1.022-1.245, I(2)=72.1%). High risk of spine fracture was observed in PPI users (1.216, 95% CI: 1.134-1.304) but not H2RA users. When considering 5 studies conducted among postmenopausal women, the RR was 1.376, (95% CI: 1.043-1.816) with modest heterogeneity (I(2)=57.7%). Subgroup analysis and sensitivity analysis found consistent association between hip fracture risk and PPI use but not H2RA use. Positive association for H2RA use lost its significance when considering case-control studies and European studies. CONCLUSION: Results of this updated meta-analysis provided evidence to support that acid-suppressive medications were associated with increased risk of fracture, especially hip fracture.
Authors: Shelly L Gray; Andrea Z LaCroix; Joseph Larson; John Robbins; Jane A Cauley; JoAnn E Manson; Zhao Chen Journal: Arch Intern Med Date: 2010-05-10
Authors: Carlen Reyes; Francesc Formiga; Marta Coderch; Jordi Hoyo; Gemma Ferriz; Jordi Casanovas; Rosa Monteserín; Carlos Brotons; Marta Rojas; Irene Moral Journal: Bone Date: 2012-09-27 Impact factor: 4.398
Authors: S Silverman; H N Viswanathan; Y-C Yang; A Wang; S Boonen; S Ragi-Eis; P Fardellone; N Gilchrist; P Lips; M Nevitt; S Palacios Gil-Antuñano; K Pavelka; D Revicki; J Simon; D Macarios; E S Siris Journal: Osteoporos Int Date: 2011-07-19 Impact factor: 4.507
Authors: Anca Trifan; Carol Stanciu; Irina Girleanu; Oana Cristina Stoica; Ana Maria Singeap; Roxana Maxim; Stefan Andrei Chiriac; Alin Ciobica; Lucian Boiculese Journal: World J Gastroenterol Date: 2017-09-21 Impact factor: 5.742
Authors: Hadiah AlMutairi; Máire O'Dwyer; Mary McCarron; Philip McCallion; Martin C Henman Journal: Saudi Pharm J Date: 2018-05-24 Impact factor: 4.330
Authors: Maximilian M Menger; Philipp Bremer; Claudia Scheuer; Mika F Rollmann; Benedikt J Braun; Steven C Herath; Marcel Orth; Thomas Später; Tim Pohlemann; Michael D Menger; Tina Histing Journal: Sci Rep Date: 2020-12-23 Impact factor: 4.379